行情

ALNY

ALNY

阿里拉姆制药
NASDAQ

实时行情|Nasdaq Last Sale

105.82
+1.61
+1.55%
盘后: 105.82 0 0.00% 17:01 04/03 EDT
开盘
101.45
昨收
104.21
最高
105.98
最低
100.02
成交量
50.14万
成交额
--
52周最高
134.51
52周最低
65.81
市值
119.65亿
市盈率(TTM)
-13.0053
分时
5日
1月
3月
1年
5年

分析师评级

21位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ALNY价格均价为141.45,最高价位200.00,最低价为75.00。

EPS

ALNY 新闻

更多
  • Covid Report: Amgen Pops As Heavyweight Biotech Enters Coronavirus Ring
  • Investor's Business Daily · 3天前
  • Vir and Alnylam Expand Collaboration to Advance Investigational RNAi Therapeutics Targeting Host Factors for the Treatment of COVID-19
  • Business Wire · 3天前
  • The Daily Biotech Pulse: Novartis Scraps Deal To Sell Sandoz Assets, Nevro Pre-Announces Q1 Shortfall, Affimed Granted Orphan Drug Designation
  • Benzinga · 3天前
  • COVID-19 actions - healthcare
  • Seeking Alpha - Article · 3天前

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

ALNY 简况

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).
展开

微牛提供Alnylam Pharmaceuticals, Inc.(NASDAQ-ALNY)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ALNY股票新闻,以帮助您做出投资决策。